iShares JPMorgan USD Emerging Markets Bond ETF vs Teladoc Health Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.17 (market cap $12.87B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is far larger — about 12.7× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Teladoc Health Inc for 39 Days on average.
| EMB | TDOC | |
|---|---|---|
Market Cap | $12.87B | $1.01B |
Volume | 14,946,002 | 4,668,477 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $9.72 |
52-Week Low | $90.14 | $4.47 |
Typical Hold Time | 51 Days | 39 Days |
Enterprise Value | — | $1.27B |
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.17, showing modest daily gains of 0.43% amid a bearish technical outlook with 14 sell signals versus 6 buy signals. The stock faces resistance at $91-92 levels while maintaining dividend distributions, though key valuation metrics remain unavailable for fundamental assessment. Recent market commentary suggests limited near-term upside potential.
The outlook remains cautious with technical indicators signaling bearish momentum and Seeking Alpha maintaining a HOLD rating as of July 23, 2026. Primary investment appeal centers on income generation through dividends, though price appreciation appears constrained. Risks include broader market volatility and emerging market bond yield fluctuations affecting fixed-income alternatives.
Teladoc Health (TDOC) trades at $5.54, down 0.36% on the day, as the stock faces bearish technical momentum despite recent earnings beats. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net income margin in 2026. Analyst sentiment is mixed with 35.7% buy ratings but a consensus price target of $8.83 suggesting 59% upside potential. Recent CFO appointment and legal officer transitions signal management changes amid ongoing operational challenges.
TDOC presents a high-risk opportunity with significant valuation discount (P/S 0.4x) but faces persistent profitability challenges. The integrated care business shows promise with improving margins, while BetterHelp weakness and negative cash flow in 2025 raise concerns. Upside depends on successful execution of turnaround strategy and achieving sustainable profitability in the competitive telehealth market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →